EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.
EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.
EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.
Company limited by guarantee
Company Registration Number:
10585826 (England and Wales)
Unaudited statutory accounts for the year ended 31 March 2023
Period of accounts
Start date: 1 April 2022
End date: 31 March 2023
EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.
Contents of the Financial Statements
for the Period Ended 31 March 2023
Directors report | |
Profit and loss | |
Balance sheet | |
Additional notes | |
Balance sheet notes | |
Community Interest Report |
EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.
Directors' report period ended
The directors present their report with the financial statements of the company for the period ended 31 March 2023
Principal activities of the company
Additional information
The objects of the company are to carry on activities that benefit the community and in particular (without limitation):To provide an administrative framework supporting the activities of External Quality Assessment (EQA) in cancer diagnostic testing in clinical laboratory sciences. It will operate on a not-for-profit basis; conform to high professional standards; act impartially; be strictly financially accountable. In order that all concerned with the quality of laboratory investigations may have confidence in the services provided, it will assess the quality of clinical laboratory testing in the areas of cancer diagnosis and prediction of treatment response. This testing is carried out in laboratories throughout the UK and worldwide, and by providing external quality assessments, the company will assist healthcare professionals to assure the quality of the work undertaken in their laboratories, which in turn will help to facilitate optimal care for cancer patients undergoing treatment for their disease in the UK and across the world.
Directors
The directors shown below have held office during the whole of the period from
1 April 2022 to 31 March 2023
The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006
This report was approved by the board of directors on
And signed on behalf of the board by:
Name:
Status: Director
EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.
Profit And Loss Account
for the Period Ended
2023 | 2022 | |
---|---|---|
| £ | £ |
Turnover: | | |
Cost of sales: | ( | ( |
Gross profit(or loss): | | |
Administrative expenses: | ( | ( |
Other operating income: | | |
Operating profit(or loss): | | |
Interest receivable and similar income: | | |
Interest payable and similar charges: | ( | |
Profit(or loss) before tax: | | |
Tax: | ( | ( |
Profit(or loss) for the financial year: | | |
EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.
Balance sheet
As at
Notes | 2023 | 2022 | |
---|---|---|---|
| £ | £ | |
Fixed assets | |||
Intangible assets: | 3 | | |
Tangible assets: | 4 | | |
Total fixed assets: | | | |
Current assets | |||
Stocks: | 5 | | |
Debtors: | 6 | | |
Cash at bank and in hand: | | | |
Total current assets: | | | |
Creditors: amounts falling due within one year: | 7 | ( | ( |
Net current assets (liabilities): | | | |
Total assets less current liabilities: | | | |
Provision for liabilities: | ( | ( | |
Total net assets (liabilities): | | | |
Members' funds | |||
Profit and loss account: | | | |
Total members' funds: | | |
The notes form part of these financial statements
EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.
Balance sheet statements
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.
Notes to the Financial Statements
for the Period Ended 31 March 2023
-
1. Accounting policies
Basis of measurement and preparation
These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102 Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Tangible fixed assets depreciation policy
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life. Intangible fixed assets amortisation policy
Intangible fixed assets are measured at cost less accumulative amortisation and any accumulative impairment losses. Amortisation is provided on all intangible fixed assets.
EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.
Notes to the Financial Statements
for the Period Ended 31 March 2023
-
2. Employees
2023 2022 Average number of employees during the period 10 9
EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.
Notes to the Financial Statements
for the Period Ended 31 March 2023
3. Intangible assets
Goodwill | Other | Total | |
---|---|---|---|
Cost | £ | £ | £ |
At 1 April 2022 | | | |
Additions | | | |
Disposals | |||
Revaluations | |||
Transfers | |||
At 31 March 2023 | | | |
Amortisation | |||
At 1 April 2022 | | | |
Charge for year | | | |
On disposals | |||
Other adjustments | |||
At 31 March 2023 | | | |
Net book value | |||
At 31 March 2023 | | | |
At 31 March 2022 | | |
EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.
Notes to the Financial Statements
for the Period Ended 31 March 2023
4. Tangible assets
Land & buildings | Plant & machinery | Fixtures & fittings | Office equipment | Motor vehicles | Total | |
---|---|---|---|---|---|---|
Cost | £ | £ | £ | £ | £ | £ |
At 1 April 2022 | | | | |||
Additions | | | | |||
Disposals | ( | ( | ||||
Revaluations | ||||||
Transfers | ||||||
At 31 March 2023 | | | | |||
Depreciation | ||||||
At 1 April 2022 | | | | |||
Charge for year | | | | |||
On disposals | ( | ( | ||||
Other adjustments | ||||||
At 31 March 2023 | | | | |||
Net book value | ||||||
At 31 March 2023 | | | | |||
At 31 March 2022 | | | |
EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.
Notes to the Financial Statements
for the Period Ended 31 March 2023
5. Stocks
2023 | 2022 | |
---|---|---|
£ | £ | |
Stocks | | |
Total | | |
EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.
Notes to the Financial Statements
for the Period Ended 31 March 2023
6. Debtors
2023 | 2022 | |
---|---|---|
£ | £ | |
Trade debtors | | |
Prepayments and accrued income | | |
Other debtors | | |
Total | | |
EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.
Notes to the Financial Statements
for the Period Ended 31 March 2023
7. Creditors: amounts falling due within one year note
2023 | 2022 | |
---|---|---|
£ | £ | |
Trade creditors | | |
Taxation and social security | | |
Accruals and deferred income | | |
Other creditors | | |
Total | | |
COMMUNITY INTEREST ANNUAL REPORT
EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.
Company Number: 10585826 (England and Wales)
Year Ending: 31 March 2023
The Company has supported the activities of a UK-based external quality assessment (EQA) scheme, which provides its services to healthcare laboratories throughout the world.Currently the number of laboratories receiving EQA services is in excess of 500, with approximately 40% of them being based in the UK.By providing these EQA services the Company through its Scheme allows laboratories to benchmark the quality of their clinical testing activities against those of its peers, providing assurance that the quality of testing is good in the vast majority of cases. Where deficiencies in test quality are identified the Scheme works with the laboratory to improve that quality, through the provision of education and advice.
There has been consultation with all stakeholder groups.1.Clinical laboratories participating in the EQA activities are provided with an annual questionnaire designed to obtain their feedback about all aspects of the EQA services. The company provides an outward-facing website, through which participants may contact the EQA Scheme.2.The EQA Scheme is part of a wider consortium of similar operations hosted by various legal entities (mainly NHS teaching hospitals). Directors from EQASCD CIC regularly attend joint meetings of that consortium group (up to 7 meetings per year).
The total amount paid or receivable by directors in respect of qualifying services was £266,793.There were no other transactions or arrangements in connection with the remuneration of directors which require to be disclosed.
No transfer of assets other than for full consideration
This report was approved by the board of directors on
29 December 2023
And signed on behalf of the board by:
Name: A R Dodson
Status: Director